Velicept raises another $15M to advance overactive bladder treatment
Velicept Therapeutics said Tuesday it raised an additional $15 million through an expansion of its series B financing.
The Malvern pharmaceutical company plans to use the funding to support the completion of two mid-stage clinical trials of its lead new drug candidate Solabegron, which it is developing as a treatment for people with overactive bladders.
Dr. James Walker, president and CEO of Velicept, said the fu nding will also enable the company to prepare for phase-III clinical studies — the…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: John George Source Type: news
More News: Biotechnology | Clinical Trials | Funding | Health Management | Overactive Bladder | Overactive Bladder Syndrome | Study